New Drug May Slow Recurrent Thyroid Cancer, Study Finds

February 12, 2015 7:00 PM

2 0

THURSDAY, Feb. 12, 2015 (HealthDay News) -- A new thyroid cancer drug can delay the progression of the disease almost five times longer than a placebo in people with recurring cancer, according to results from a new clinical trial.

The oral drug, lenvatinib, is a targeted therapy that fights cancer by deterring the growth of new blood vessels that could help feed the cancer, researchers said.

Read more

To category page